Clinical Research
Copyright ©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. May 7, 2005; 11(17): 2626-2629
Published online May 7, 2005. doi: 10.3748/wjg.v11.i17.2626
Table 1 Patient characteristics.
Age (yr)Gender (%)Performance (%)Weight loss (%)Histologic type status (%)
Range 35-87Male (70)KPS≥70 to 95<575%Squamous cell carcinoma (60)
Median 66Female (30)KPS<70 to 5≥525%Adenocarcinoma (14) Undifferentiated large cell (24) NSCLC, OT (2)
Table 2 Concurrent chemotherapy agents used.
Patients (n)Concurrent chemotherapy
25Cisplatin and etoposide
4Cisplatin
2Cisplatin, etoposide, and gemcitabine
6Cisplatin and 5-fluorouracil
1Cisplatin and Navelbine
5Cisplatin, Navelbine and gemcitabine
5Carboplatin and Taxol
3Gemcitabine
3Taxotere
Table 3 RTOG grading for acute esophageal injury.
GradeDescription
0No change
1Mild dysphagia or odynophagia, requiring topical anesthetic, non-narcotic agents, or soft diet
2Moderate dysphagia or odynophagia, requiring narcotic agents or liquid diet
3Severe dysphagia or odynophagia with dehydration or weight loss (>15% of pretreatment baseline), requiring nasogastric feeding
4Complete stricture, ulceration, perforation or fistula
5Death
Table 4 Distribution of acute and late esophageal injury.
Pt. no.Late esophageal injuryAcute esophageal injury
133
213
333
433
513
624
733
831
935
1031
1123
1233
1333
1445
1503
1633
Total1114
Table 5 Analysis of factors predicting esophageal injury.
VariableUnivariate (P)Multivariate (P)
Concurrent chemotherapy0.00010.0090
Maximal dose point ≥60 Gy0.00010.0010
Mean esophageal dose ≥40 Gy0.03410.1023
Carinal or subcarinal nodes0.01450.2136
Sequential chemotherapy0.36800.1467
Volume >55 Gy0.16990.1235
Age (yr)0.30640.1354
Gender0.49470.1213
Weight loss0.36080.1302